Generic placeholder image

Current Drug Safety


ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Research Article

Intercycle Unplanned Hospital Admissions Due to Cisplatin-based Chemotherapy Regimen-induced Adverse Reactions: A Retrospective Analysis

Author(s): Heber Rew Bright*, Sujith J. Chandy, Raju Titus Chacko and Selvamani Backianathan

Volume 14 , Issue 3 , 2019

Page: [182 - 191] Pages: 10

DOI: 10.2174/1574886314666190619123047


Background: Cisplatin is a commonly used chemotherapy agent known to induce serious adverse reactions that may require hospital readmission. We aimed to analyze the extent and factors associated with unplanned hospital admissions due to cisplatin-based chemotherapy regimen-induced adverse reactions.

Methods: Retrospective review of medical records of those patients who received at least one cycle of chemotherapy with cisplatin-based regimen during a six-month period from March to August 2017.

Results: Of the 458 patients who received cisplatin during the study period, 142 patients did not meet inclusion criteria. The remaining 316 patients had a total of 770 episodes of primary admissions for chemotherapy administration. Overall, 187 episodes (24%) of intercycle unplanned hospital admission were recorded of which a major proportion (n=178; 23%) was due to chemotherapy-induced adverse reactions. Underweight patients had higher odds of unplanned admission (OR 1.77, 95% confidence interval [CI] 1.11 to 1.77). Significantly, more number of patients with cancers of head and neck and cancers of musculoskeletal were readmitted (p<0.001). Compared to high-dose cisplatin, low- and intermediate-dose cisplatin had lesser odds of unplanned admission (OR 0.52 and 0.77; 95% CI, 0.31 to 0.88 and 0.41 to 1.45, respectively). Patients without concomitant radiotherapy, drug-drug interaction and initial chemotherapy cycles had lesser odds of unplanned admission (OR 0.38, 0.50 and 0.52; 95% CI, 0.26 to 0.55, 0.25 to 0.99 and 0.32 to 0.84 respectively). Unplanned admissions were mainly due to blood-related (31%) and gastrointestinal (19%) adverse reactions. Among chemotherapy regimens, cisplatin monotherapy (34%) and cisplatin with doxorubicin (20%) regimens resulted in a major proportion of unplanned admissions.

Conclusion: These findings highlight risk factors that help identify high-risk patients and suggest that therapy modifications may reduce hospital readmissions due to cisplatin-based chemotherapy-induced adverse reactions.

Keywords: Adverse drug reaction, hospital readmission, cisplatin, associated factors, cancer treatment, causality.

Graphical Abstract
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 2014; 740: 364-78.
Astolfi L, Ghiselli S, Guaran V, et al. Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation. Oncol Rep 2013; 29(4): 1285-92.
Surendiran A, Balamurugan N, Gunaseelan K, Akhtar S, Reddy K, Adithan C. Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. Indian J Pharmacol 2010; 42(1): 40-3.
Sumiyoshi M, Soda H, Sadanaga N, et al. Alert regarding cisplatin-induced severe adverse events in cancer patients with xeroderma pigmentosum. Intern Med 2017; 56(8): 979-82.
Pujol J-L, Lafontaine T, Quantin X, et al. Neoadjuvant Etoposide, Ifosfamide, and Cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer. Chest 1999; 115(1): 144-50.
Otty Z, Skinner MB, Dass J, et al. Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients. Asia Pac J Clin Oncol 7(3): 287-92.
Felix HC, Seaberg B, Bursac Z, Thostenson J, Stewart MK. Why do patients keep coming back? results of a readmitted patient survey. Soc Work Health Care 2015; 54(1): 1-15.
Bell JF, Whitney RL, Reed SC, et al. Systematic review of hospital readmissions among patients with cancer in the United States. Oncol Nurs Forum 2017; 44(2): 176-91.
Donzé J, Lipsitz S, Bates DW, Schnipper JL. Causes and patterns of readmissions in patients with common comorbidities: Retrospective cohort study. BMJ 2013; 347.
Ji H, Abushomar H, Chen X-K, Qian C, Gerson D. All-cause readmission to acute care for cancer patients. Healthc Q 2012; 15(3): 14-6.
El Morabet N, Uitvlugt EB, van den Bemt BJF, van den Bemt PMLA, Janssen MJA, Karapinar-Çarkit F. Prevalence and preventability of drug-related hospital readmissions: A systematic review. J Am Geriatr Soc 2018; 66(3): 602-8.
Steventon A, Billings J. Preventing hospital readmissions: The importance of considering ‘impactibility,’ not just predicted risk. BMJ Qual Amp Saf 2017; 26(10): 782.
Hospital-wide 30-day risk-standardized readmission measure. Centers for Medicare & Medicaid Services; 2011.[cited 2018 Jun 20] Available from: Quality-Initiatives-Patient-Assessment-Instruments/MMS/downloads/MMSHospital-WideAll-ConditionReadmissionRate.pdf
The use of the WHO-UMC system for standardised case causality assessment. World Health Organization [cited 2018 Jun 20]. Available from: safety_efficacy/WHOcausality_assessment.pdf
Brana I, Siu LL. Locally advanced head and neck squamous cell cancer: Treatment choice based on risk factors and optimizing drug prescription. Ann Oncol 2012; 23(10): x178-85.
Brown E, Burgess D, Li C, Canter R, Bold R. Hospital readmissions: Necessary evil or preventable target for quality improvement. Ann Surg 2014; 260(4): 583-91.
Shapiro JS, Humeniuk MS, Siddiqui MA, Bonthu N, Schroeder DR, Kashiwagi DT. Risk factors for readmission in patients with cancer comanaged by hospitalists. Am J Med Qual 2017; 32(5): 526-31.
Solomon R, Egorova N, Franco R, Bickell NA. Thirty-day readmissions in metastatic cancer patients: Room for improvement? J Clin Oncol 2017; 35(15): 6541.
Epstein AS, Crosbie C, Martin SC, et al. 30-day-or-sooner readmissions of gastrointestinal medical oncology patients following cancer center inpatient service discharge: Characteristics and preventability. Hosp Pract 2014; 42(5): 34-44.
Ghiam MK, Langerman A, Sargi Z, Rohde S. Head and neck cancer patients: Rates, reasons, and risk factors for 30-day unplanned readmission. Otolaryngol Head Neck Surg 2018; 159(1): 149-57.
Berry JG, Gay JC, Joynt MK, et al. Age trends in 30 day hospital readmissions: US national retrospective analysis. BMJ 2018; 360Available from: . [abstract].
González JR, Fernandez E, Moreno V, et al. Sex differences in hospital readmission among colorectal cancer patients. J Epidemiol Community Health 2005; 59(6): 506.
Chang H-T, Chen C-K, Lin M-H, Chou P, Chen T-J, Hwang S-J. Readmissions in cancer patients after receiving inpatient palliative care in Taiwan: A 9-Year Nationwide population-based cohort study. Medicine (Baltimore) 2016; 95(8): e2782.
Sebastian MR, Hergenroeder A. Does rate of weight gain during hospitalization predict readmission in adolescents with eating disorders? J Adolesc Health 2014; 54(2): S78-9.
Reinke CE, Kelz RR, Zubizarreta JR, et al. Obesity and readmission in elderly surgical patients. Surgery 2012; 152(3): 355-62.
Zai AH, Ronquillo JG, Nieves R, Chueh HC, Kvedar JC, Jethwani K. Assessing hospital readmission risk factors in heart failure patients enrolled in a telemonitoring program. Int J Telemed Appl 2013; 2013: 305819.
Andersen KK, Olsen TS. The obesity paradox in stroke: Lower mortality and lower risk of readmission for recurrent stroke in obese stroke patients. Int J Stroke 2013; 10(1): 99-104.
Manzano J-GM, Gadiraju S, Hiremath A, Lin HY, Farroni J, Halm J. Unplanned 30-Day readmissions in a general internal medicine hospitalist service at a comprehensive cancer center. J Oncol Pract 2015; 11(5): 410-5.
Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350(19): 1945-52.
Wolfe D, Yazdi F, Kanji S, et al. Incidence, causes, and consequences of preventable adverse drug reactions occurring in inpatients: A systematic review of systematic reviews. PLoS One 2018; 13(10): e0205426.
Min S, Zheng Q, Zhang B, et al. A meta-analysis of efficacy and adverse effects of lobaplatin and cisplatin in the treatment of malignant pleural effusion. Cancer 2019; 22(2): 90-8.
Suh WN, Kong KA, Han Y, et al. Risk factors associated with treatment refusal in lung cancer. Thorac Cancer 2017; 8(5): 443-50.

© 2022 Bentham Science Publishers | Privacy Policy